Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 11/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068168 | 1.00 | DDB1 (0.40) | DDB1CRBNGSK3BPDCD1CD274 | |
| SCHEMBL31068400 | 1.00 | DDB1 (0.40) | DDB1CRBNGSK3BPDCD1CD274 | |
| SCHEMBL29348592 | 0.90 | DDB1 (0.41) | DDB1CRBNPDCD1CD274 | |
| SCHEMBL29348355 | 0.88 | PRKAB2 (0.43) | DDB1CRBNPDCD1CD274 | |
| SCHEMBL29348391 | 0.87 | DDB1 (0.39) | DDB1CRBNPDCD1CD274IKZF2 | |
| SCHEMBL29348436 | 0.85 | CRBN (0.44) | DDB1CRBN | |
| SCHEMBL29348660 | 0.83 | DDB1 (0.39) | DDB1CRBNCD274IKZF2 | |
| SCHEMBL29348614 | 0.83 | CRBN (0.41) | DDB1CRBNCD274IKZF2 | |
| SCHEMBL29348400 | 0.82 | CRBN (0.46) | DDB1CRBNPDCD1CD274 | |
| SCHEMBL31068261 | 0.82 | DDB1 (0.47) | DDB1CRBNPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |